UNSPSC 51282700: Glycopeptides

Glycopeptides

UNSPSC 51282700 Glycopeptides is a Class code whose recent state and local solicitations show no alignment with the nominal code scope — instead, the opportunities tracked under this code cover emergency response pharmaceuticals, naloxone, over-the-counter medical supplies, and generic multi-source pharmaceuticals for state health and human services programs. State and local buyers under this classification are primarily health agencies, emergency management bodies, and cooperative purchasing alliances; the issuing bodies include county health departments, state health and human services commissions, municipal fire departments, and multistate purchasing consortia. The work being solicited ranges from annual procurement of naloxone and drug deactivation systems for community health initiatives, to emergency medical supplies for fire rescue divisions, to manufacturer contracts for generic pharmaceuticals and OTC products distributed through state and local healthcare facilities and employee benefit plans.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, due July 26, 2023. The City of Tampa Purchasing Department posted IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000, designating the opportunity as sheltered for certified Small Local Business Enterprises with a 5 percent bid discount not to exceed $10,000. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on behalf of Minnesota and Oregon in January 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor information on direct-to-manufacturer prescription fulfillment programs supporting therapeutic pharmacy initiatives.